Exactech, Inc. (EXAC) PT Set at $34.00 by Robert W. Baird

Robert W. Baird set a $34.00 price objective on Exactech, Inc. (NASDAQ:EXAC) in a research note published on Sunday, October 15th. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also issued research reports about the stock. Gabelli restated a buy rating on shares of Exactech in a research note on Monday, July 31st. BidaskClub upgraded shares of Exactech from a sell rating to a hold rating in a research note on Friday, August 18th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $42.00.

Exactech (NASDAQ:EXAC) opened at 41.85 on Friday. Exactech has a 12-month low of $22.20 and a 12-month high of $42.55. The stock has a market cap of $600.46 million, a PE ratio of 804.81 and a beta of 1.01. The company’s 50-day moving average price is $32.78 and its 200-day moving average price is $30.48.

Exactech (NASDAQ:EXAC) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.33. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The firm had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $67.75 million. During the same quarter last year, the company posted $0.31 earnings per share. Exactech’s revenue was up 1.8% on a year-over-year basis. On average, equities analysts expect that Exactech will post $1.29 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Exactech, Inc. (EXAC) PT Set at $34.00 by Robert W. Baird” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/robert-w-baird-analysts-give-exactech-inc-exac-a-34-00-price-target.html.

In related news, Director Fern Watts sold 1,013 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total transaction of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at $137,272.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can acquired a new position in Exactech in the second quarter worth approximately $134,000. Russell Investments Group Ltd. grew its position in Exactech by 13.2% in the second quarter. Russell Investments Group Ltd. now owns 47,118 shares of the medical equipment provider’s stock worth $1,405,000 after buying an additional 5,485 shares during the last quarter. OxFORD Asset Management LLP grew its position in Exactech by 17.8% in the second quarter. OxFORD Asset Management LLP now owns 59,972 shares of the medical equipment provider’s stock worth $1,787,000 after buying an additional 9,082 shares during the last quarter. Prudential Financial Inc. acquired a new position in Exactech in the second quarter worth approximately $359,000. Finally, Schwab Charles Investment Management Inc. grew its position in Exactech by 14.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 53,918 shares of the medical equipment provider’s stock worth $1,359,000 after buying an additional 6,742 shares during the last quarter. Institutional investors and hedge funds own 64.09% of the company’s stock.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply